HAVCR2 and neoplasm: Targeting PD-1, CTLA4, LAG3, or TIM3 axis may be a potential immunotherapy-based combination strategy to enhance population of cytotoxic effector T cells in patients with high level of Rab37+/PD-1+/TIM3+ tumor-infiltrating CD8+ T cells [40–45].